Recent Research Analysts’ Ratings Updates for Insulet (PODD)

A number of firms have modified their ratings and price targets on shares of Insulet (NASDAQ: PODD) recently:

• 6/27/2026 – Insulet was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/24/2026 – Insulet was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/23/2026 – Insulet is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $190.00 price target on the stock.
• 6/11/2026 – Insulet was given a new $219.00 price target by UBS Group AG.
• 6/11/2026 – Insulet had its price target lowered by Truist Financial Corporation from $250.00 to $219.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Insulet was given a new $216.00 price target by Raymond James Financial, Inc..
• 6/1/2026 – Insulet had its price target lowered by TD Cowen from $379.00 to $294.00. They now have a “hold” rating on the stock.
• 5/28/2026 – Insulet had its price target lowered by Citigroup Inc. from $175.00 to $165.00. They now have a “neutral” rating on the stock.
• 5/27/2026 – Insulet had its “buy” rating reaffirmed by Benchmark Co..
• 5/27/2026 – Insulet had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $205.00 price target on the stock.
• 5/27/2026 – Insulet had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $280.00 price target on the stock.
• 5/26/2026 – Insulet had its price target lowered by BTIG Research from $260.00 to $235.00. They now have a “buy” rating on the stock.
• 5/20/2026 – Insulet is now covered by William Blair. They set an “outperform” rating on the stock.
• 5/18/2026 – Insulet had its price target lowered by Bank of America Corporation from $288.00 to $208.00. They now have a “buy” rating on the stock.
• 5/15/2026 – Insulet was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 5/12/2026 – Insulet is now covered by Benchmark Co.. They set a “buy” rating on the stock.
• 5/9/2026 – Insulet was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/7/2026 – Insulet was given a new $237.00 price target by The Goldman Sachs Group, Inc..
• 5/7/2026 – Insulet had its price target lowered by Royal Bank Of Canada from $325.00 to $280.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Truist Financial Corporation from $315.00 to $250.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Sanford C. Bernstein from $330.00 to $200.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Barclays PLC from $286.00 to $198.00. They now have an “underweight” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Stifel Nicolaus from $350.00 to $250.00.
• 5/7/2026 – Insulet had its price target lowered by Raymond James Financial, Inc. from $355.00 to $263.00.
• 5/7/2026 – Insulet had its price target lowered by Evercore Inc from $240.00 to $200.00.
• 5/7/2026 – Insulet had its price target lowered by Canaccord Genuity Group Inc. from $435.00 to $249.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Leerink Partners from $360.00 to $247.00.
• 5/7/2026 – Insulet had its price target lowered by Jefferies Financial Group Inc. from $400.00 to $360.00.
• 5/7/2026 – Insulet had its price target lowered by Citigroup Inc. from $230.00 to $175.00.
• 5/7/2026 – Insulet had its price target lowered by Robert W. Baird from $360.00 to $248.00.
• 5/7/2026 – Insulet had its price target lowered by JPMorgan Chase & Co. from $340.00 to $275.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – Insulet had its price target lowered by Oppenheimer Holdings, Inc. from $300.00 to $210.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Insulet had its “neutral” rating reaffirmed by Citigroup Inc..
• 5/6/2026 – Insulet had its price target lowered by Piper Sandler from $360.00 to $210.00.
• 5/6/2026 – Insulet had its price target lowered by Wells Fargo & Company from $360.00 to $255.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Insulet had its price target lowered by BTIG Research from $320.00 to $260.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Insulet was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.36% of the company’s stock.

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.